The GLP1 pharmacological agonist, liraglutide, was used via a subcutaneous injection daily for 24 weeks in glucose-intolerant NASH patients and significantly improved liver function and histological features. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.